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The Journal of Immunology
Impairment of CCR6+ and CXCR3+ Th Cell Migration in
HIV-1 Infection Is Rescued by Modulating Actin
Polymerization
Valentina Cecchinato,* Enos Bernasconi,† Roberto F. Speck,‡ Michele Proietti,*
Ulrike Sauermann,x Gianluca D’Agostino,* Gabriela Danelon,* Tanja Rezzonico Jost,*
Fabio Grassi,*,{ Lorenzo Raeli,* Franziska Scho¨ni-Affolter,‖ Christiane Stahl-Hennig,x
Mariagrazia Uguccioni,*,# and the Swiss HIV Cohort Study1
CD4+ T cell repopulation of the gut is rarely achieved in HIV-1–infected individuals who are receiving clinically effective
antiretroviral therapy. Alterations in the integrity of the mucosal barrier have been indicated as a cause for chronic immune
activation and disease progression. In this study, we present evidence that persistent immune activation causes impairment
of lymphocytes to respond to chemotactic stimuli, thus preventing their trafficking from the blood stream to peripheral organs.
CCR6+ and CXCR3+ Th cells accumulate in the blood of aviremic HIV-1–infected patients on long-term antiretroviral therapy,
and their frequency in the circulation positively correlates to levels of soluble CD14 in plasma, a marker of chronic immune
activation. Th cells show an impaired response to chemotactic stimuli both in humans and in the pathogenic model of SIV
infection, and this defect is due to hyperactivation of cofilin and inefficient actin polymerization. Taking advantage of a murine
model of chronic immune activation, we demonstrate that cytoskeleton remodeling, induced by okadaic acid, restores lymphocyte
migration in response to chemokines, both in vitro and in vivo. This study calls for novel pharmacological approaches in those
pathological conditions characterized by persistent immune activation and loss of trafficking of T cell subsets to niches that sustain
their maturation and activities. The Journal of Immunology, 2017, 198: 184–195.
I
nfection with HIV-1 in humans is characterized by a severe
depletion of memory CD4+ T cells, both in the blood and in
the mucosal compartment (1), and by impaired immune re-
sponses to many pathogens (2). CD4+ T cell reduction during
infection has been associated not only with direct viral cytotox-
icity (3), but with a more generalized state of chronic immune
activation, which contributes to cell loss and to immune dysfunc-
tion, ultimately leading to disease progression (4, 5). This hypoth-
esis is corroborated by many studies indicating that: 1) during
infection the markers of immune activation are increased, and they
correlate with a poor prognosis (6–9); 2) proinflammatory cytokines
and chemokines are expressed at high levels in the lymphoid organs
of SIV-infected macaques and of HIV-1–infected patients (10–12);
3) prolonged immune activation in mice models results in T cell
immunodeficiency (13) and in lymphoid architecture disruption
(14); and 4) natural hosts of SIV, which despite the high viral load
do not progress to AIDS, have a much lower immune activation
than that found in pathogenic models of SIV infection (15).
A possible cause of chronic systemic immune activation is the
translocation of microbial products from the gastrointestinal mu-
cosa to the circulation, due to virologic and immunologic events
(16–19). Indeed, plasma levels of LPS are increased in chronically
HIV-1–infected patients and SIV-infected macaques and correlate
with markers of immune activation, such as the frequency of cir-
culating CD38+HLA-DR+CD8+ T cells or plasma levels of soluble
CD14 (sCD14) (16). An important role in the maintenance of the
integrity of the mucosal barrier has been attributed to Th17 cells
(20), a subset of Th cells that are depleted in HIV-1 (21), and in
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pathogenic SIV infection (22, 23). In contrast, nonpathogenic models
of SIV infection as well as elite controller patients maintain normal
frequencies of Th17 cells (21, 24, 25).
Although long-term antiretroviral therapy (ART) is able to re-
store Th17 cells in the bloodstream, only a partial reconstitution is
achieved in the mucosal compartment (26–28). The mechanisms
leading to a preferential depletion of Th17 cells have been par-
tially elucidated: several studies have shown that Th17 cells are
more permissive than Th1 cells to HIV-1 infection both in vitro
and in vivo (29–32). Although Th1 cells, which express the chemokine
receptors CXCR3, CCR5, and CXCR4, have been shown to be
relatively resistant to HIV infection in vitro (29), the predominant
susceptibility of Th17 cells to some HIV strains has been linked to
the expression of the chemokine receptors CCR6, CCR9, CCR5,
and of the integrin a4b7, which are also essential for their homing
to the intestinal mucosa (33–35). In the SIV infection model it has
been demonstrated that, despite effective ART, intestinal Th17 cell
function is severely impaired (36), suggesting that during prolonged
viral suppression, the incomplete gut reconstitution of this sub-
population accounts for the maintenance of persistent chronic im-
mune activation.
Leukocyte migration to tissues is controlled by the local ex-
pression of chemokines, which trigger an intracellular cascade of
events resulting in cytoskeleton reorganization (37). In particular,
F-actin generation results in a change of cell shape, which is es-
sential for effective migration, and depends on many cellular
factors involved in the remodeling of F-actin stores. Among
these, cofilin is an actin-severing protein that, in its active non-
phosphorylated form, binds to the end of F-actin and cleaves the
filaments into shorter fragments. On one side this process reduces
intracellular F-actin stores, but on the other side it also introduces
new substrates for further actin polymerization (38). Phosphory-
lation on Ser3 by LIM kinase-1 leads to cofilin inactivation and
inhibits the ability of this protein to depolymerize F-actin (39, 40).
In this study, we have elucidated mechanisms that might be
responsible for a poor repopulation of Th cells in the gut of HIV-
1–infected patients, despite successful treatment with ART. We
found that CCR6+ and CXCR3+ Th cells accumulate in the blood
of treated patients, their frequency in the circulation correlates
with chronic immune activation, and that CCR6+ cells are de-
pleted in the colonic lamina propria of SIV-infected macaques. In
HIV-1–infected patients regardless of therapy and in SIV-infected
macaques, migration of Th cells in response to chemotactic
stimuli is impaired and is associated with perturbation of actin
polymerization. Using an in vivo model (14), we demonstrate that
chronic immune activation per se is sufficient to dampen Th cell
migration, which can be restored by pharmacological modulation
of cytoskeleton activity.
Materials and Methods
Ethics statement
Colony-bred rhesus monkeys of Indian origin were housed at the German
Primate Center under standard conditions according to the German Animal
Welfare Act, which complies with the European Union guidelines on the use
of nonhuman primates for biomedical research. Animals belonged to studies
approved by the Ethics Committee authorized by the Lower Saxony State
Office for Consumer Protection with the project licenses 33.14-4502-04-
017/07, 33.14.42502-04-072/08, and 33.14-42502-04-10/0037. According
to section 11 of the German Animal Welfare Act, the German Primate
Center is permitted to breed and house nonhuman primates under license no.
392001/7 issued by the local veterinary authorities. Measures of animal
welfare and reduction of suffering comprise a 12:12 h light/dark schedule,
provision of dry monkey biscuits supplemented with fresh fruit or vege-
tables twice daily, and fresh water access ad libitum. Additionally, for
environmental enrichment, animals were offered feeding puzzles, varying
toys, and wood sticks for gnawing. Monkeys were kept under permanent
health care supervision by trained staff and veterinarians. Moreover, su-
pervision and advice were provided by the institutional welfare officer as
demanded by the German Animal Welfare Act. SIV-infected rhesus ma-
caques were caged in groups of two or three animals, permitting social
behavior. In case of suffering predefined by a scoring system on termination
criteria, monkeys were humanely killed in deep anesthesia by an overdose
of pentobarbital given i.v.
C57BL/6 mice were maintained in the specific pathogen-free animal
facility of the Institute for Research in Biomedicine. All animal experiments
were performed in accordance with the Swiss Federal Law (Animal Welfare
Act RS 455, Tierschutzgesetz, https://www.admin.ch/opc/de/classified-
compilation/20022103/index.html) and the Cantonal rules on experi-
ments with animals (Regolamento Cantonale sulla Protezione degli Animali).
The experiments were evaluated by the Cantonal animal experimentation
committee (Comitato Etico Cantonale del Ticino, Switzerland) and approved
under authorization no. TI17/2010.
HIV-1–infected patients were recruited from the Swiss HIV Cohort
Study (SHCS). The SHCS was approved by the local ethical committees of
the participating centers (Kantonale Ethikkommission Z€urich [KEK-ZH-NR:
EK-793]; Comitato Etico Cantonale, Repubblica e Cantone Ticino [CE 813]),
and written informed consent was obtained from all participants.
Animals
For this study 63 adult colony-bred rhesus monkeys of Indian origin
comprising 17 naive and 46 experimentally infected with SIVmac239 or
SIVmac251 between 4 and 12 y old were used. Animals had been infected
by the i.v., intrarectal, or tonsillar route with SIVmac251 or SIVmac239, and
blood was collected either in the early postacute phase (weeks 5–6 post-
infection, n = 6) or in the late-chronic phase of infection (.13 wk post-
infection, n = 40). Intestinal biopsies were collected longitudinally from
six animals before infection (preinfection), 10 d postinfection, and 13 wk
postinfection, as described before (41). To obtain blood samples animals
were sedated intramuscularly with 10 mg of ketamine per kilogram body
weight. For deeper anesthesia required for the collection of intestinal bi-
opsies or as premedication for euthanasia, a mixture of ketamine, xylazine,
and atropine was injected i.m.
A total of 110 C57BL/6 mice were purchased from Harlan Laboratories
(Udine, Italy). Age- and sex-matched mice (6–8 wk old) were randomly
assigned to two groups that were injected i.p. for 7 d either with PBS
(control, n = 50) or with 0.1 mg/kg/d R848 (n = 50). Air pouches were
established in R848-treated and in controls animals by injecting s.c. 5 and
3 ml of air at day 0 and day 3, respectively. At day 6, mice were injected in
the air pouch with 1000 pmol CXCL12, 1000 pmol okadaic acid (OA),
or with a combination of 1000 pmol CXCL12 and 1000 pmol OA. PBS
(200 ml) was injected to determine basal cell recruitment. After 6 h, cells
were collected from the air pouch and analyzed by flow cytometry. To
calculate the total cell number in Peyer’s patches (PP), all the PP from the
entire intestine were collected from R848-treated and control mice. Cells
were recovered after mechanical destruction and counted to obtain the total
number of cells in PP per intestine (cells per intestine). Cells were then
stained with the indicated Abs to determine the frequency of different
subpopulations and analyzed by flow cytometry. Spleens from 10 untreated
C57BL/6 mice (6–8 wk old) were collected to obtain cells for in vitro
experiments to assess the influence of R848 on cell proliferation, apo-
ptosis, and migration.
Patients
We enrolled 58 HIV-1–infected patients who were followed in the SHCS
(http://www.shcs.ch) (42). Patients were divided into three groups according
to their CD4 nadir count and the use of ART in the last 3 y. Group A
comprised 15 ART-naive patients. Group B included 29 patients on ART
for.3 y and with a CD4 nadir of,100 cells/ml of blood. Group C included
14 patients on ART for .3 y and with a CD4 nadir of .350 cells/ml of
blood. Exclusion criteria included opportunistic infections, acute somatic
diseases, neoplastic diseases, immune-suppressive therapies, and chronic
hepatitis B virus or hepatitis C virus coinfection. Features of all patients are
shown in Table I.
Cell isolation
PBMCs were isolated from peripheral blood of both human and macaque
specimens using Ficoll-Hypaque density centrifugation within 24 h from
blood withdrawal. PBMCs from healthy donors (HD) were isolated from
buffy coats (Central Laboratory of the Swiss Red Cross, Basel, Switzerland),
whereas blood from HIV-1–infected patients was collected in BDVacutainer
CPT cell preparation tubes containing sodium citrate as anticoagulant
(362782; BD Biosciences). Total CCR6+ and CXCR3+ cells, which includes
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B and T lymphocytes, were isolated from PBMCs by a first incubation with
anti–CCR6-PE (11A9; BD Pharmingen) or anti–CXCR3-PE (1C6; BD
Pharmingen), followed by PE magnetic beads sorting (Miltenyi Biotec).
For the experiments performed with cells from HD exposed to plasma
from HIV-1–infected patients, CD4+ cells were enriched using CD4
magnetic beads (Miltenyi Biotec), and CCR6+CD45RA2 cells were sorted
using BD FACSAria III (BD Biosciences).
Monocytes were isolated from PBMCs using CD14 magnetic beads
(Miltenyi Biotec), and monocyte-derived dendritic cells (mo-DCs) were
generated as previously described (43). Briefly, CD14+ cells were cultured for
4 d in RPMI 1640 medium supplemented with 10% FCS, 1000 U/ml IL-4, and
50 ng/ml GM-CSF. Cells were then stimulated overnight either with LPS
(2mg/ml) or withCandida albicans (at the ratio of 3:1) and the supernatants were
collected to evaluate CCL20 and CXCL10 production by stimulated mo-DCs.
Murine splenocytes were isolated after mechanical destruction of the
spleen, followed by red blood cell lysis according to standard protocols.
CD4+ T cells were isolated from splenocytes using CD4 magnetic beads (LT34;
Miltenyi Biotec). For experiments in which splenocytes were cultured in the
presence of R848, enriched CD4+ splenocytes were sorted using a BD FACSAria
III (BD Bioscences) as naive CCR62 (CD4+CD252CD62L+CD442CCR62),
memory CCR62 (CD4+CD252CD44+CCR62), or memory CCR6+
(CD4+CD252CD44+CCR6+) CD4+ cells.
Flow cytometric analysis
For surface staining of human and macaque specimens, cell suspensions
were incubated with the appropriate combination of the following mAbs:
CD3-allophycocyanin-Cy7 (SP34-2; BD Pharmingen), CD4-PerCP-Cy5.5
(L200; BD Pharmingen), CD20-FITC (2H7; AbD Serotec), CD45RA-
FITC (ALB11; Beckman Coulter), CCR6-PE (11A9; BD Pharmingen),
CCR7-PE-Cy7 (3D12; BD Pharmingen), CXCR3–Alexa Fluor 488 (1C6;
BD Pharmingen), CXCR3-PE (1C6; BD Pharmingen).
For intracellular staining, cells were fixed for 30 min with cold para-
formaldehyde (4%) in PBS and permeabilized for 2 min with 0.1% Triton
X-100. Staining was then performed using rabbit mAbs specific for cofilin
(D3F9; Cell Signaling Technology), or phospho-cofilin (Ser3) (77G2; Cell
Signaling Technology), followed by anti-rabbit IgG–Alexa Fluor 633 (A-2107;
Life Technologies).
Surface staining of murine specimens was performed using a combination
of the following mAbs: CD3-PE (145-2C11; BioLegend), CD3–Alexa Fluor 647
(17A2; BioLegend), CD4-FITC (GK1.5; BioLegend), CD4-PerCP (GK1.5;
BioLegend), CD25-PE-Cy7 (PC61; BioLegend), CD44-FITC (IM7; BioLegend),
CD45R/B220–Pacific Blue (RA3-6B2; BioLegend), CD45R/B220-PerCP-Cy5.5
(RA3-6B2; eBioscience), CD62L-allophycocyanin (MEL-14; eBioscience),
F4/80-allophycocyanin-Cy7 (BM8; BioLegend), Gr1-biotin (RB6-8C5; BD
Pharmingen), CD11b-PE-Cy7 (M1/70; BioLegend), CXCR4-PE (L276F12;
BioLegend), CXCR3–Brilliant Violet 421 (CXCR3-173; BioLegend),
CCR6-PE (29-2L17; BioLegend).
The samples were acquired with BD LSRFortessa (BD Biosciences), and
the results were analyzed with FlowJo software (Tree Star). Relative mean
fluorescence intensity (rMFI) was calculated as the ratio between stained
and unstained samples; gating strategy is provided in Supplemental Fig. 1A.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues were cut into 5-mm slices and
used for immunohistochemistry. Ag retrieval was performed with Dako target
retrieval solution (pH 6, S1699) according to the manufacturer’s instructions,
and the slides were incubated with the appropriate primary Ab for 2 h at room
temperature. For Ag detection the following primary Abs were used: rabbit
anti-human CD3 (1 mg/ml, A0452; Dako), mouse anti-human CXCL10
(1 mg/ml, 33036; R&D Systems), mouse anti-human CCR6 (0.5 mg/ml,
53103; R&D Systems), mouse anti-human CXCR3 (0.5 mg/ml, 49801;
R&D Systems), rabbit-anti human CCL20 (0.5 mg/ml, ab9829; Abcam),
mouse anti-human CD4 (1:100 dilution, 1F6; AbD Serotec), and rat anti-
mouse CCR6 (2.5 mg/ml, 18B9E6; Novus Biologicals). Detection of positive
cells was achieved using a MACH 4 universal HRP polymer detection kit
mouse/rabbit (M4U534H) or rat-on-mouse HRP polymer (RT517G) from
Biocare Medical, according to the manufacturer’s instructions. Images were
acquired using a340/0.95 numerical aperture Plan Apo objective on a Nikon
Eclipse E800 upright microscope, equipped with the digital camera DXM1200
(Nikon), and using Act-1 software version 2.7 (Nikon). Quantitative analysis was
performed with a custom-made macro, using the open-source image analysis
software Fiji (44). Images were composed in Photoshop CS5 (Adobe).
Quantitative real-time PCR and plasma viral load in macaques
RNA extraction was performed using standard protocols, after isolation and
resuspension in TRIzol reagent (15596; Invitrogen). Retrotranscription was
performed using Moloney murine leukemia virus reverse transcriptase
(28025; Invitrogen) at 500 ng of RNA per sample and 250 ng of random
primers, according to the manufacturer’s instructions. TaqMan gene ex-
pression assays from Applied Biosystems were used to detect specific
transcript levels (protocol as suggested by the manufacturer): CFL1
Hs02621564_g1, 18S rRNA 4352930E. The following set of primers/probe
was used to detect HIV1-NEF: 59-GCACGGCAAGAGGCGA-39 (forward
primer), 59-GAGGTGGGTTGCTTTGATAGAG-39 (reverse primer),
59-CGGCGACTGGA AGAAGCGGAGA-39 (FAM Probe) as previously
described (45). The 7900HT fast real-time PCR system (Applied Bio-
systems) was used to perform the detection. Data were normalized on the
specific 18S rRNA values and expressed as arbitrary units.
Viral RNA copies were quantified in purified SIV RNA from plasma
using TaqMan-based real-time PCR on an ABI Prism 7500 sequence de-
tection system (Applied Biosystems) as described (46).
Chemokine and sCD14 detection
The concentration of CCL20 in the supernatant of human mo-DCs was
determined using a sandwich ELISA kit (DM3A00; R&D Systems),
according to the manufacturer’s protocol. CXCL10 levels in the superna-
tant of human mo-DCs were determined using the BD cytometric bead
array human IP-10 flex set (558280; BD Biosciences), according to the
manufacturer’s instructions. The concentration of human sCD14 in the
plasma of HD and HIV-1–infected patients was determined using a sand-
wich ELISA kit (DC140; R&D Systems), according to the manufacturer’s
protocol.
Chemotaxis assay
HTS Transwell-96 permeable support with 3.0-mm pore polycarbonate
membrane (3386; Corning) were used to assess migration of CCR6+ or
CXCR3+ cells isolated from human or macaque PBMCs or of murine
CD4+ splenocytes isolated from C57BL/6 mice. Briefly, after an overnight
culture, 15 3 104 cells were diluted in chemotaxis buffer (RPMI 1640
supplemented with 0.05% pasteurized human albumin) and added to the
upper wells. For assessing chemotaxis of human or macaque cells,
recombinant human CCL20 or CXCL10 (R&D Systems) was diluted in
chemotaxis buffer and added to the bottom wells. For assessing chemotaxis
of murine cells, recombinant mouse CCL20 or CXCL12 (R&D Systems)
was diluted in chemotaxis buffer and added to the bottom wells. For cofilin
inhibition assays, 250 nM OA was added to the chemokine in the bottom
wells. Migration was allowed to proceed for 90 min at 37˚C in 5% CO2.
Migrated cells were collected from the bottom well, stained with CD3-
allophycocyanin-CY7, CD4-PercP-Cy5.5, and CD20-FITC, suspended in a
fixed volume, and counted at constant speed with a BD LSRFortessa.
Chemotaxis index was calculated as the fold increase in the number of
migrated cells in response to chemokine over the spontaneous cell mi-
gration in response to chemotaxis buffer alone.
Cell tracking
CD4+CCR6+CD45RA2 sorted T cells were stained with 5 mM CFSE,
using the CellTrace CFSE cell proliferation kit (C34554; Invitrogen Mo-
lecular Probes) according to the manufacturer’s instructions. Ninety-
six–well flat-bottom plates were precoated with 10 mg/ml fibronectin, and
a total of 1 3 104 cells/well were seeded in 100 ml of RPMI 1640 medium
supplemented with 5% human plasma from HD or a pool of plasma from
five HIV-1–infected patients under long-term ART. After 1 h at 37˚C in
5% CO2, cell random movements were recorded for 3 h, using the BD
Pathway 855 imager, acquiring a picture every 2 min for both trans-
mitted light and green fluorescence for CFSE, to check the viability and
perform cell tracking, with an Olympus Plan N 310, numerical aperture
of 0.30 objective. Track mean speed (micrometers per minute) was
obtained by tracing the spots in the fluorescence channel using Bitplane
Imaris 8.0.
Actin polymerization assay
F-actin content was determined with FITC-coupled phalloidin (P5282;
Sigma-Aldrich) in human CCR6+ or CXCR3+ cells following chemokine
receptor triggering as previously described (47). Briefly, stimulations were
performed with 100 nM CCL20 or 100 nM CXCL10, respectively. The
reaction was stopped after 15 s and cells were fixed for 30 min with cold
paraformaldehyde (4%) in PBS. After fixation, cells were permeabilized
with 0.1% Triton X-100, stained with 4 mg/ml FITC-conjugated phalloidin,
and analyzed by flow cytometry. For cofilin inhibition assays, cells were
preincubated for 15 min at 37˚C in the absence or presence of 250 nM OA.
All stimulations were performed in duplicate. F-actin content is indicated as
MFI in unstimulated and stimulated cells.
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In vitro R848 treatment of murine splenocytes
CD4+ splenocytes were isolated through magnetic bead sorting (LT34;
Miltenyi Biotec) from 10 untreated C57BL/6 mice (6–8 wk old). Briefly,
flat-bottom 96-well plates were coated for 4 h at 37˚C with 2 mg/ml anti-
CD3E (145-2C11; BioLegend) and 2 mg/ml anti-CD28 (37.51; BioLegend)
Abs. Total CD4+ or sorted naive CCR62, memory CCR62, and memory
CCR6+CD4+ splenocytes were seeded at 5 3 104 cells/well in complete
medium (RPMI 1640 supplemented with 10% FCS, 13 nonessential amino
acids, 1 mM sodium pyruvate, 20 mM GlutaMAX, 50 mM 2-ME, 50 U/ml
penicillin, and 50 mg/ml streptomycin) in the presence or absence of 1 mg/ml
R848. After 72 h, cell migration induced by murine CCL20 (described in
Chemotaxis assay), proliferation, apoptosis, and CCR6 expression in CCR6+
and CCR62 subpopulations were assessed.
Cell proliferation was evaluated by the CFSE dilution method. Briefly,
total CD4+ splenocytes were stained with 2.5 mMCFSE, using the CellTrace
CFSE cell proliferation kit (C34554; Invitrogen Molecular Probes)
according to the manufacturer’s instructions. After 72 h, cells were stained
for 30 min at 4˚C with the anti–CCR6-PE (29-2L17; BioLegend) Ab and
acquired with a BD LSRFortessa (BD Biosciences). Frequency of prolif-
erating cells was determined in CCR6+ and CCR62 populations. Apoptosis
was evaluated by flow cytometric determination of annexin V staining in the
CCR6+ and CCR62 populations. Briefly, total CD4+ splenocytes were
stained for 30 min at 4˚C with the anti–CCR6-PE (29-2L17; BioLegend) Ab.
After surface staining, cells were stained with annexin V–FITC in 13 binding
buffer (10 mM HEPES [pH 7.4], 140 mM NaOH, 2.5 mM CaCl2) for 15 min
at room temperature in the dark and acquired with a BD LSRFortessa (BD
Biosciences).
Statistical analysis
Data are presented as mean 6 SEM. The statistical significance between
two groups was determined using a nonparametric two-tailed Mann–
Whitney U test or a paired t test. The statistical significance between more
than two groups was evaluated using a Kruskal–Wallis test followed by a
Dunn multiple comparison adjustment, or two-way ANOVA followed by
a Bonferroni adjustment where appropriate. Correlation was assessed
using Spearman rank-order correlation. A p value ,0.05 was considered
statistically significant. Data were analyzed using GraphPad Prism
version 5.0.
Results
CCR6+ and CXCR3+ Th cell dynamics in experimental SIV
infection
To analyze the dynamics of CCR6+ and CXCR3+ Th cells during
the course of SIV infection, we have assessed their frequency by
flow cytometry in a cohort of uninfected and SIV-infected rhesus
macaques either at the postacute set point or in the chronic phase
of infection. The frequency of circulating CCR6+ and CXCR3+ Th
cells declined very rapidly during the course of infection (Fig. 1A).
Later on, during the chronic phase, CD4+ T cells remained low,
whereas CCR6+ and CXCR3+ Th cells tended to recover (Fig. 1A),
and all frequencies were negatively correlated with plasma viral
load (Fig. 1B).
Interestingly, circulating CCR6+ and CXCR3+ cells from SIV-
infected macaques poorly migrated in response to the selective
chemokines CCL20 and CXCL10 both in the acute and in the
chronic phase of infection (Fig. 1C). Of note, this reduction was
not related to the expression of chemokine receptors on cell
surface, as no changes during infection were detected for CCR6,
whereas the expression of CXCR3 was diminished only during the
acute phase and subsequently recovered (Fig. 1D).
FIGURE 1. CCR6+ and CXCR3+ Th cell frequencies during experimental SIV infection. (A) Frequency of circulating CD3+CD4+, CCR6+CD4+, and
CXCR3+CD4+ T cells in 17 uninfected normal controls (NC) or 22 SIV-infected macaques, either in the postacute (Ac, n = 6) or in the chronic (Ch, n = 16)
phase of infection. (B) Correlation analysis between plasma viral load at week 16 postinfection and the frequency of CD3+CD4+, CCR6+CD4+, and
CXCR3+CD4+ T cells in 24 chronically infected macaques. Data were analyzed using the Spearman rank correlation method, and p and r values are
indicated in the figure for each plot. (C) Migration induced by CCL20 or CXCL10 in CCR6+ or CXCR3+ cells from uninfected normal controls (NC, n = 5),
and SIV-infected macaques in the postacute (Ac, n = 3) or in the chronic (Ch, n = 5) phase of infection. Means 6 SEM of migrated cells are shown. (D)
CCR6 or CXCR3 expression on total lymphocyte measured by flow cytometry in uninfected normal controls (NC, n = 11) or SIV-infected macaques in the
postacute (Ac, n = 6) or chronic (Ch, n = 5) phase of infection. Horizontal bars represent the mean value. *p, 0.05, **p, 0.01, ***p, 0.001 by Kruskal–
Wallis test with a multicomparison Dunn adjustment (A, C, and D).
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Immunohistochemical analysis of the colonic lamina propria
from SIV-infected macaques, performed on serial tissue sections,
confirmed intestinal CD4+ cell depletion during the course of in-
fection, and it revealed that this was paralleled by a decrease of
CCR6+ cells (Fig. 2A). The expression of CCL20, the selective
CCR6 agonist, was not downmodulated during the infection and
was mainly observed in the epithelial layer (Fig. 2B). Both CD3+
and CXCR3+ cells were significantly increased in the chronic
phase of infection, most likely accounting for CD8+CXCR3+
T cells recruited by CXCL10, a selective chemokine for CXCR3,
which was also found to be expressed in the lamina propria of
SIV-infected macaques (Fig. 2).
CCR6+ and CXCR3+ Th cell dynamics in HIV-1 infection:
effect of ART
To analyze the effect of ARTon the dynamics of circulating CCR6+
and CXCR3+ Th cells during the course of HIV-1 infection, we
studied untreated and ART-treated patients from the SHCS. A
total of 58 patients were enrolled in the study and divided into
three groups according to their therapeutic regimen and CD4 nadir.
Untreated HIV-1–infected patients were represented in group A,
whereas patients under long-term ART (.3 y) were allocated to
groups B and C and divided according to the level of immunode-
ficiency reached (CD4 nadir of ,100 cells/ml or .350 cells/ml of
blood, respectively). Patients were characterized for treatment, ab-
solute CD4 counts in blood, plasma viral load, and distribution of
CD4+ naive, central memory, and effector memory T cells at the
time when the specimen was taken for further analyses (Supplemental
Fig. 1B, 1C, Table I).
A significant increase in the frequency of circulating CCR6+ Th
cells was found in group B as compared with HD, and indeed the
absolute number of these cells increased in all patients under long-
term ART, reaching significance in patients from group C (Fig. 3A,
Supplemental Fig. 1D). Moreover, similar results were observed in
the frequency and absolute number of CXCR3+ Th cells (Fig. 3B,
Supplemental Fig. 1E). In untreated HIV-1–infected patients from
group A, regression analysis using the Spearman rank correlation
method showed that plasma viral load negatively correlated with the
frequency of total CD4+ T cells (p = 0.0055, r = 20.69), but not
with the frequency of CD4+ Th cells expressing either CCR6
(p = 0.49) or CXCR3 (p = 0.97) (data not shown).
Significantly higher levels of sCD14 were found in the plasma of
ART-treated HIV-1–infected patients as compared with HD, in-
dicating persistence of immune activation (Fig. 3C), which is not
abolished in the absence of circulating virus. Of note, no corre-
lation was found between sCD14 and the frequency of circulating
CD4+ Th cells (p = 0.64, r = 20.14), whereas sCD14 positively
correlated with the frequencies of CCR6+ and CXCR3+ Th cells
(Fig. 3D), showing a higher significance in the pool of central
memory T cells (Fig. 3E).
Impairment of cell migration is maintained in ART-treated
HIV-1–infected individuals
Given the impairment in cell migration observed in the untreated
SIV infection model, we decided to analyze the migratory capacity
of circulating CCR6+ and CXCR3+ Th cells that accumulate in the
blood of ART-treated patients.
Circulating CCR6+ and CXCR3+ cells from HIV-1–infected
patients showed, similar to what was observed in SIV-infected
macaques, a strong impairment in the response to both CCL20
and CXCL10. Most importantly, ART did not improve the ability
of CCR6+ cells to respond to CCL20, nor of CXCR3+ cells to
respond to CXCL10, suggesting that long-term efficient reduction
in viral load to mostly undetectable levels is not sufficient to re-
store the ability of these cells to respond to chemotactic stimuli
(Fig. 3F, Supplemental Fig. 2A). Cell migration impairment in
response to CCL20 was mostly affecting CD4+ T cells, whereas
CD8+ T cell migration was decreased only in HIV-1–infected
patients from group B (Supplemental Fig. 2B). As observed in
SIV infected macaques, no changes were found in the expression
of CCR6 and CXCR3 in cells from HIV-1–infected patients
compared with HD (Fig. 3G). In vitro cell tracking showed that
CCR6+ Th cells from HD, exposed to plasma from aviremic
HIV-1–infected patients under ART, randomly moved signifi-
cantly slower on fibronectin compared with exposure to HD
plasma (Fig. 3H).
FIGURE 2. Reduced number of CCR6+ cells in the gut lamina propria of SIV-infected macaques. (A) Quantification of CD4+, CD3+, CCR6+, and
CXCR3+ cells in the colon of three SIV-infected macaques at different time points during infection (normal controls [NC], preinfection; acute [Ac] in-
fection, 10 d postinfection; chronic [Ch] infection, 13 wk postinfection). Data are presented as means6 SEM. (B) Immunohistochemical staining of CCR6,
CCL20, CXCR3, and CXCL10 in colon biopsies from three SIV-infected macaques at different time points during infection. Positive cells, detected with
the diaminobenzidine substrate, are shown in brown. One representative image for each staining is shown. Original magnification, 340; scale bar, 200 mm.
*p , 0.05 by Kruskal–Wallis test with a multicomparison Dunn adjustment (A).
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In line with the finding that CCL20 production at mucosal sites is
maintained during SIV infection (Fig. 2B), mo-DCs from HIV-
1–infected patients retained their capacity to secrete both CCL20
and CXCL10 following LPS or Candida albicans stimulation
(Supplemental Fig. 2C).
Cytoskeleton machinery impairment in HIV-1 infection is
rescued by OA
We analyzed the ability of CCR6+ and CXCR3+ cells from HD and
the three groups of HIV-1–infected patients to polymerize actin,
which is an essential process during cellular migration. The levels
of intracellular F-actin in both CCR6+ and CXCR3+ cells were
significantly lower in HIV-1–infected patients compared with HD,
both at the basal level and following chemokine stimulation
(Fig. 4A). Although cells from patients were able to respond to the
stimuli, actin polymerization in HIV-1–infected patients, and in
particular in the ART-treated ones from group B (p , 0.05,
Fig. 4B), was lower compared with HD. This might indicate that,
after stimulation, the threshold required to induce an effective
migration is not reached by the cells from the patients.
HIV-1 is able to hijack the cellular cytoskeleton machinery to
increase viral entry and integration in the host genome (48, 49). In
particular, the viral protein nef from HIV-1 has been shown to
inhibit cofilin activity, thus reducing actin polymerization turnover
(50). In the samples we analyzed, nef mRNA was not detectable,
neither in viremic nor in ART-treated HIV-1–infected patients
(data not shown); on the contrary, a significant increase of total
and phosphorylated cofilin was found in lymphocytes from HIV-
1–infected patients compared with HD (Fig. 4C). Interestingly, the
ratio of phosphorylated cofilin over total cofilin was significantly
lower in lymphocytes from HIV-1–infected patients compared
with HD, thus indicating a higher activity of the protein during HIV-1
infection (Fig. 4D), with no differences between untreated and treated
individuals (data not shown). The increase in the total amount of cofilin
was not due to an upregulation of its mRNA level (Fig. 4E). These data
indicate a higher and not efficient actin polymerization turnover,
resulting in inefficient response to chemotactic stimuli.
On the basis of the above results, we decided to promote actin
polymerization by using OA, a toxin able to induce cytoskeleton
reorganization, also by activating LIM kinase-1, which is re-
sponsible for turning off cofilin activity (51). In vitro OA treatment
was able to rescue F-actin formation (Fig. 4F) and most impor-
tantly cell migration (Fig. 4G) of both CCR6+ and CXCR3+ cells
from HIV-1–infected patients (group B), without altering the re-
sponse to these chemokines in cells from HD (Supplemental Fig. 3),
pointing out a direct effect of cofilin in dampening the response to
chemokines in HIV-1 infection.
Chronic immune activation reduces Th cell migration both
in vitro and in vivo
Chronic immune activation is a common feature of both treated and
untreated HIV-1 infection. Therefore, it could account for the
impaired cell migration that we have found, despite ART therapy,
in all groups of HIV-1–infected patients. To assess this hypothesis,
we used an established in vivo model (14) to mimic chronic im-
mune activation by systemically injecting the TLR7/8 agonist
R848 in C57BL/6 mice. The treatment induced a significant in-
crease in the frequency of circulating CCR6+ Th cells, but it did
not affect circulating CXCR3+ and CXCR4+ Th cells (Fig. 5A).
CCR6+ Th cells isolated from the spleen poorly migrated in re-
sponse to CCL20, despite a similar CCR6 expression in treated
and untreated animals (Fig. 5B). To verify whether the impairment
occurs before an evident accumulation of circulating Th cells, and
whether it is selective for CCR6+ Th cells, we next analyzed the
response to a receptor, CXCR4, which is broadly expressed by
leukocytes. Similar to what we observed for CCR6+ Th cells, total
CD4+ T cell migration in response to CXCL12 was reduced, but it
Table I. HIV-1–infected patients included in the study
Patient ID ART
Absolute CD4
(Cells/ml
Blood)
Viral Load
(mRNA
Copies/ml
Plasma) Age (y) Sex
Group A
PT-1 No 663 93,685 41 M
PT-2 No 584 3,306 53 M
PT-3 No 581 89,386 32 M
PT-4 No 482 45,332 34 F
PT-5 No 1621 4,229 35 M
PT-6 No 525 66,325 31 M
PT-7 No 462 25,490 24 M
PT-8 No 361 18,119 41 F
PT-9 No 820 14,115 28 M
PT-10 No 1269 197 61 M
PT-11 No 688 0 54 F
PT-12 No 189 228,635 49 M
PT-13 No 1162 0 51 M
PT-14 No 289 171,400 55 M
PT-15 No 695 11,412 51 M
Group Ba
PT-16 Yes 657 0 57 M
PT-17 Yes 579 0 35 F
PT-18 Yes 212 0 56 F
PT-19 Yes 247 0 40 M
PT-20 Yes 803 0 47 M
PT-21 Yes 500 0 51 M
PT-22 Yes 827 0 69 M
PT-23 Yes 1097 0 51 M
PT-24 Yes 678 0 49 M
PT-25 Yes 331 0 40 M
PT-26 Yes 378 93 47 M
PT-27 Yes 369 0 51 M
PT-28 Yes 435 69 50 M
PT-29 Yes 772 0 48 F
PT-30 Yes 840 0 49 M
PT-31 Yes 318 0 45 M
PT-32 Yes 684 0 50 M
PT-33 Yes 388 0 79 M
PT-34 Yes 400 0 53 M
PT-35 Yes 203 0 79 M
PT-36 Yes 559 0 49 F
PT-37 Yes 359 0 62 M
PT-38 Yes 870 34 51 M
PT-39 Yes 512 0 67 M
PT-40 Yes 381 0 61 M
PT-41 Yes 558 0 63 M
PT-42 Yes 337 0 53 M
PT-43 Yes 786 0 42 F
PT-44 Yes 629 0 71 M
Group Cb
PT-45 Yes 843 0 46 M
PT-46 Yes 2176 0 44 F
PT-47 Yes 1020 22 45 M
PT-48 Yes 798 0 51 M
PT-49 Yes 629 ,20 37 M
PT-50 Yes 905 0 53 M
PT-51 Yes 915 0 61 M
PT-52 Yes 586 0 55 M
PT-53 Yes 823 0 44 M
PT-54 Yes 644 0 42 M
PT-55 Yes 816 4,653 40 M
PT-56 Yes 786 0 56 M
PT-57 Yes 963 0 41 M
PT-58 Yes 877 0 40 M
Demographic characteristics, treatment, absolute CD4 counts in blood, and
plasma viral load of the 58 HIV-1–infected individuals enrolled in the study are
shown.
aCD4 nadir of ,100 cells/ml of blood.
bCD4 nadir of .350 cells/ml of blood.
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was not ascribed to downmodulation of CXCR4 on the cell surface
(Fig. 5C). The accumulation of CCR6+ Th cells observed in the
blood of treated mice was not due to a direct effect of R848 on
apoptosis of CCR62 cells, proliferation of CCR6+ cells, or induc-
tion of CCR6 expression in the CCR62 population (Supplemental
Fig. 4A–C). Of note, CCR6+ Th cells, isolated from the spleen of
untreated mice, lost their ability to migrate in response to CCL20
when stimulated in vitro with R848 (Supplemental Fig. 4D).
The analysis of the PP from treated mice revealed a significant
decrease in the total cell number, as well as in CD4+ Th cells
(Fig. 6A), which was associated with a significant reduction of
CCR6+ cells as assessed by immunohistochemistry (Fig. 6B).
These data further corroborate the hypothesis that impairment in
cell migration may account for the reduced T cell numbers in the
gut mucosa, and that this impairment is due to chronic immune
activation, in addition to a direct effect of the virus. Similar to the
data obtained with cells from HIV-1–infected patients, OA was
able to partially restore in the R848-treated mice the migration of
both total CD4+ and CCR6+ Th cells (Fig. 6C).
To assess whether OA can modulate the effect of chronic im-
mune activation on cell migration in vivo, air pouches were gen-
erated in R848-treated and untreated mice and, given the low
frequency of CCR6+ Th cells present in the circulation of mice
housed in specific pathogen-free conditions, we measured the
number of CD4+ T cells recruited in response to CXCL12. As
observed in the in vitro experiments, CD4+ T cells of treated mice
were not able to efficiently respond to the chemokine. Strikingly,
this impairment was rescued by the injection of OA together with
CXCL12 in the air pouches (Fig. 6D), indicating that the drug
injected at the abluminal sites can favor, similar to the in vitro
experiments, a cytoskeleton remodeling of the leading edge in
cells patrolling the skin endothelium. This was sufficient to restore
T cell capacity to respond to chemotactic cues.
Discussion
The dynamics of different subsets of circulating Th cells in the
course of HIV-1 infection have beenwidely investigated with the help
of the expression of specific tissue-homing markers. Nevertheless, a
FIGURE 3. CCR6+ and CXCR3+ Th cells accumulate in the blood during HIV-1 infection and poorly migrate in response to CCL20 or CXCL10. Th cells
in the blood of 23 HD and 58 HIV-1–infected patients from the three groups were analyzed. (A and B) Frequency and absolute numbers of circulating
CCR6+CD4+ (A) or CXCR3+CD4+ T cells (B). (C) Concentration of sCD14 in the plasma of 10 HD and 14 HIV-1–infected individuals from the three
groups [(A), n = 8; (B), n = 5; (C), n = 1]. (D and E) Correlation analysis between plasma levels of sCD14 and the frequency of total (D) or central memory
(Cm) (E) CCR6+ or CXCR3+ Th cells in 14 HIV-infected individuals from the three groups [(A), light gray; (B), dark gray; (C), black]. Data were analyzed
using the Spearman rank correlation method, and p and r values are indicated in the figure for each plot. (F) Migration of CCR6+ and CXCR3+ cells at
optimal concentrations of CCL20 or CXCL10, respectively, in at least 5 HD and 19 HIV-1–infected patients. Horizontal bars represent the mean value. (G)
CCR6 and CXCR3 expression on total lymphocytes measured by flow cytometry in 23 HD and in 58 HIV-1–infected patients. Horizontal bars represent the
mean value. rMFI represents the ratio between stained and unstained samples. (H) Track mean speed of lymphocytes isolated from HD and exposed to
plasma from HD or HIV-1-infected patients (HIV+). One representative out of three experiments performed with cells from different donors is shown.
Horizontal bars represent the mean value. *p , 0.05, **p , 0.01, ***p , 0.001 by Kruskal–Wallis test with a multicomparison Dunn adjustment (A, B, F,
and G), nonparametric two-tailed Mann–Whitney U test (C and H).
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functional analysis on Th cell ability to respond to selective chemokine
receptor agonists is missing. For the first time, to our knowledge, we
have elucidated the relationship among the degree of immunodefi-
ciency, cell recovery following ART treatment, and the ability of Th
cells to respond to chemoattractants. This study discloses a novel path
occurring in viral infection that, after the clearance of circulating
virus, can impair the host immune system.
We show that CCR6+ and CXCR3+ Th cells accumulate in the
blood of ART-treated HIV-1–infected patients, and their fre-
quencies correlate with a status of chronic immune activation. Cell
accumulation is most likely due to their incompetence to respond
to chemokines, thus preventing their trafficking to peripheral or-
gans. Although the impaired migration of Th cells is a common
feature of both SIV and HIV-1 infection, their accumulation in the
blood becomes evident only in patients successfully treated by
ART. Regardless of therapy, circulating lymphocytes from HIV-1–
infected patients, which show a compromised migration, are
characterized by inefficient actin polymerization in response to
chemotactic stimuli and express high levels of active cofilin,
which contribute to an increased process of F-actin severing. By
modulating the cytoskeleton activity, we were able to rescue both
optimal levels of intracellular F-actin and efficient cell migration
following chemokine receptor triggering. For the first time, to our
knowledge, we show in a mouse model that mimics the immu-
nological alterations observed in HIV-1 infection (14) that chronic
immune activation leads to CCR6+ Th cell accumulation in the
circulation. This is associated with a reduced number of CD4+
T cells in the PP, as well as an impairment of lymphocyte migration
that can be reverted by modulating the cytoskeleton activity.
In untreated HIV-1–infected patients, and in line with previ-
ously published data (29, 52), we show a significant decrease in
the frequency of CD4+CCR6+ effector memory T cells, which
speaks for this cell type being a major target for HIV-1 (29, 31).
The present study shows that, although the frequency of central
memory CCR6+ T cells increased in patients with a low (,100 cells/ml
of blood, group B) and high (.350 cells/ml of blood, group C) CD4
nadir, the highest numbers of circulating CCR6+ Th cells were found in
patients with a high CD4 nadir (Supplemental Fig. 1D). Indeed, in the
FIGURE 4. Reduced levels of actin polymerization are associated with increased activity of cofilin in lymphocytes from HIV-1–infected patients and are
restored by OA. (A and B) Actin polymerization in lymphocytes isolated from 6 HD and 15 HIV-1–infected patients from the three groups [(A), n = 5; (B),
n = 5; (C), n = 5]. F-actin was measured as phalloidin-FITC MFI in cells untreated or treated for 15 s with CCL20 or CXCL10, respectively. Data are
presented as means 6 SEM of untreated and treated cells (A), whereas (B) shows the single values of treated cells in the different groups of patients. (C)
Expression of cofilin and P-cofilin measured by flow cytometry in total lymphocytes from 10 HD and 12 HIV-1–infected patients from groups A (n = 5) and
C (n = 7). Box plots: minimum to maximum. rMFI represents the ratio between stained and unstained samples. (D) Cofilin activity in lymphocytes,
measured as the ratio of P-cofilin over total cofilin in 10 HD and 12 HIV-1–infected patients from groups A (n = 5) and C (n = 7). Horizontal bars represent
the mean value. (E) mRNA expression of cofilin (CFL-1) in total PBMCs from HD and from HIV-1–infected patients. Values are presented as arbitrary units
(AU) over 18 s from five samples in each group. (F) Actin polymerization in lymphocytes isolated from HIV-1–infected patients from group B and
preincubated in the absence (control [CTRL]) or presence of OA. F-actin content was measured as in (A), and data are presented as means 6 SEM from at
least three independent experiments. (G) Migration of lymphocytes isolated from HIV-1–infected patients from group B in response to the indicated
chemokines, either alone or in combination with OA. Data are presented as means 6 SEM of migrated cells of five independent experiments. *p , 0.05,
**p , 0.01, ***p , 0.001 by nonparametric two-tailed Mann–Whitney U test (A, C, and D), Kruskal–Wallis test with a multicomparison Dunn adjustment
(B and E), paired t test (F and G).
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absence of circulating virus, CCR6+ Th cells can be generated but
accumulate in the bloodstream of ART-treated patients. Regarding
CXCR3+ Th cells, we found a significant increase in their frequency
both in untreated and treated patients, regardless of their CD4 nadir,
thus confirming the data from Gosselin et al. (29) and indicating that
they are not a primary target for HIV-1 (29, 31).
Mavigner et al. (53) have shown an accumulation of CCR9+ Th
cells in the circulation of ART-treated patients and suggested that,
due to a decrease in the expression of the attracting chemokine
CCL25 in the epithelium of the intestine, T cells coming into the
gut are reduced, thus preventing a complete repopulation of this
tissue. Our data on SIV-infected macaques suggest that during
untreated infection the loss of CCR6+ cells in the intestine is the
consequence of a combination of both direct viral cytotoxicity and
inefficient response to chemokines, which prevents homing to the
gut and is not associated with a decrease in mucosal CCL20
production or downmodulation of CCR6 expression. Indeed, no
changes in CCL20 expression in the intestine of SIV-infected
macaques were reported in a previous study (54). The altered
response to chemokines that we have also observed in ART-
treated, aviremic patients might contribute to inefficient cell mi-
gration into the intestine, thus preventing a complete repopulation
of this compartment.
Inefficient cell migration is not specific for CCR6+ cells, but it
could be the outcome of a more generalized impairment in
lymphocyte trafficking. We also show that CXCR3+ cells, both
from SIV-infected macaques and HIV-1–infected patients, are not
able to efficiently respond to CXCL10 in vitro, and this is again
not due to changes in receptor expression. This hypothesis is
further supported by the work from Perez-Patrigeon et al. (55)
who have shown a reduction in the migration of T cells expressing
CCR7 in HIV-1–infected patients, despite normal levels of the che-
mokine receptor expression. The increased number of CD8+CXCR3+
cells in the intestine of untreated SIV-infected animals suggests
that CD8+ cells are still able to home to the gut despite persistent
immune activation and high viral load. Our data on CCR6+ cells
from HIV-1-infected patients argue for a different migratory im-
pairment of CD4+ versus CD8+ cells (Supplemental Fig. 2B), and
they call for further studies assessing differences in response to se-
lective chemokines.
The molecular mechanisms responsible for these observed im-
pairments are far from being fully elucidated. Overexpression of
the viral protein nef, by reducing cofilin activity, inhibits dynamic
actin remodeling, thus reducing cellular migration both in vitro and
in vivo (50, 56). Cofilin and the actin pathways are also directly
modulated by HIV-1 gp120 that, by triggering CXCR4, is able to
hijack the cytoskeleton machinery, favoring viral entry and inte-
gration into the host genome (48, 51, 57). We show ex vivo that
cofilin activity is increased, rather than reduced, in all groups of
HIV-1–infecetd patients. Its activation is associated with impair-
ment in actin polymerization, both at the basal level and upon
chemokine receptor engagement, and it is not related to nef ex-
pression. Wu et al. (58) also showed increased cofilin activity in
T cells from ART-treated patients, and they suggested its direct
involvement in the abnormal T cell homing and migration ob-
served in HIV infection. Our data further support the hypothesis
that effective ART, despite suppressing plasma viral load and in-
creasing the number of circulating Th cells, is not able to fully
restore Th cell functions. Of note, exposure of CD4+CCR6+ cells
from healthy donors to plasma from ART-treated patients with
undetectable viral load is sufficient to reduce cell movement. Fur-
ther studies assessing the activity of sera from patients with per-
sistent viral infections are needed to identify the factor responsible
for this impairment and to determine whether this is a common
feature of diseases characterized by chronic immune activation.
In this study we prove that optimal levels of actin polymerization
and efficient cell migration can be restored in cells from HIV-
1–infected patients by modulating the pathway leading to actin
polymerization with OA, thus establishing the missing link be-
tween aberrant cofilin activation and reduced T cell migration. OA
represents a useful tool for modulating actin polymerization
in vitro, but its usage in vivo is limited due to its high toxicity.
FIGURE 5. In vivo chronic immune activation reduces lymphocyte migration induced by chemokines. (A) Frequency of circulating CCR6+, CXCR3+,
and CXCR4+ Th cells in at least five controls (CTRL) and five R848-treated mice. Box plots: minimum to maximum. (B) Left panel, Migration of CCR6+
cells isolated from the spleen of five CTRL or five R848-treated mice, in response to murine CCL20. Values were calculated as the percentage of CCR6+
cells migrated in comparison with the actual input of CCR6+ cells. Means 6 SEM of migrated cells are shown. Right panel, CCR6 expression on Th cells
(rMFI) in CTRL and in R848-treated mice. Horizontal bars represent the mean value. rMFI represents the ratio between stained and unstained samples. (C)
Left panel, Migration of CD4+ cells isolated from the spleen of five controls or five R848-treated mice in response to murine CXCL12. Means 6 SEM of
migrated cells are shown. Right panel, CXCR4 expression on Th cells (rMFI) in CTRL and in R848-treated mice. Horizontal bars represent the mean value.
rMFI represents the ratio between stained and unstained samples.**p, 0.01, ***p, 0.001 by nonparametric two-tailed Mann–Whitney U test (A–C), two-
way ANOVA with a Bonferroni adjustment (B and C). CTRL, control.
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Increasing evidence shows that not only persistent viral ssRNA,
but also ssRNA and DNA from a variety of pathogens, including
bacteria, protozoa, and fungi, can be sensed by the host immune
system through TLR7/8 and TLR9 triggering (59, 60). This trig-
gering affects a variety of cells, leading to cytokine production and
immune activation. Indeed, in the current paradigm of HIV-
1–associated immune activation, indirect effects via triggering
innate immune cells are essential for the development and main-
tenance of immune deficiency (61, 62). By taking advantage of an
established murine model, which recapitulates chronic immune
activation occurring in HIV-1 infection (14), we could prove that
persistent immune activation via TLR7 triggering results in the re-
tention of CCR6+ Th cells in the bloodstream and in the impairment
of lymphocyte response to chemotactic stimuli. Moreover, in
treated mice the altered traffic to the mucosal compartment is
highlighted by the reduction in both total and CCR6+ cells present
in the PP.
As proof of concept that efficient T cell migration can be restored
by acting on the cytoskeleton, we used the air pouch model, which
allows treatment with OA in a restricted skin area for a short period
of time. We demonstrated that migratory capacity can be restored
also in vivo, and we suggest how this model can be also developed
for testing new compounds, with lower systemic toxicity, with the
aim of targeting the cytoskeleton machinery in a number of diseases
where chronic immune activation is part of the pathogenic features.
In conclusion, our findings imply a novel role for chronic im-
mune activation during HIV-1 infection, which dampens the ability
of leukocytes to respond to chemotactic stimuli, thus preventing a
complete tissue reconstitution both in viremic and in ART-treated
HIV-1–infected patients.
This study has many potential implications not only for the
treatment of HIV-1–infected patients, but also for those expe-
riencing persistent infections, which lead to chronic immune
activation. Both in homeostasis and, for example, during vac-
cination protocols, it would be necessary to pharmacologically
restore the capacity of their T cells to traffic to peripheral or-
gans, and to reach niches able to support their maturation and
subsequent functions.
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